Skip to main content

Advertisement

Log in

Neuropsychiatric systemic lupus erythematosus

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The treatment of patients with neuropsychiatric systemic lupus erythematosus (NPSLE) can be difficult and complex owing to the variety of nervous system manifestations that can occur, which include peripheral nerve disease, headaches, seizures, cerebrovascular disease, chorea, transverse myelitis, and psychiatric and cognitive disorders. Many of these manifestations can result from metabolic abnormalities or infection or as side effects of medications. Thus, in any patient with suspected NPSLE, it is crucial to exclude secondary causes of the presenting symptoms before assuming that they are due to NPSLE. It is especially important to exclude infection because this is a common cause of both morbidity and mortality in patients with systemic lupus erythematosus (SLE). Symptoms such as anxiety and depression may or may not be related to disease activity. Treatment decisions are based on accurate diagnosis of the specific NPSLE manifestation, which is usually made using tools such as brain imaging, electroencephalography, cerebrospinal fluid analysis, nerve conduction studies, or special serologic tests (eg, determination of antiphospholipid or antiribosomal P antibody levels). It is also important to assess the degree of other SLEmediated systemic disease activity in a patient with neurologic manifestations to determine if activation of systemic disease activity is also occurring. This is done by measuring complement levels, anti-double-stranded DNA levels, complete blood count, and urinalysis. For some NPSLE manifestations (eg, infrequent seizures, headaches, depression, anxiety, or peripheral neuropathy) that appear without activation of systemic disease, symptomatic treatment is appropriate. For others (eg, psychosis, delirium, or transverse myelopathy without other obvious cause), treatment with high-dose glucocorticoids with or without cyclophosphamide is appropriate whether there is evidence of other systemic disease activity or not. In general, the activity and severity of the leading organ manifestations dictate pharmacologic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sabbadini MG, Manfredi AA, Bozzolo E, et al.: Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999, 8:11–19.

    Article  PubMed  CAS  Google Scholar 

  2. Sibbitt WL, Sibbitt RR, Brooks WM: Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999, 42(10):2026–2038. The major neuroimaging findings related to neuropsychiatric lupus syndromes are reviewed.

    Article  PubMed  Google Scholar 

  3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42(4):599-608. The major neuropsychiatric lupus syndromes are reviewed. Nomenclature and criteria for diagnosis are discussed.

  4. Georgescu L, Mevorach D, Arnett FC, et al.: Anti-P antibodies and neuropsychiatric lupus erythematosus. Ann N Y Acad Sci 1997, 823:263–269.

    Article  PubMed  CAS  Google Scholar 

  5. West SG, Emlen W, Wener MH, et al.: Neuropsychiatric lupus erythematosus: a 10-year experience on the value of diagnostic tests. Am J Med 1995, 99:153–163.

    Article  PubMed  CAS  Google Scholar 

  6. Shah NM, Khamashta MA, Atsumi T, et al.: Outcome of patients with anticardiolipin antibodies: a 10-year follow-up of 52 patients. Lupus 1998, 7:3–6.

    Article  PubMed  CAS  Google Scholar 

  7. Toubi E, Khamashta MA, Panarra A, et al.: Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995, 99:397–401.

    Article  PubMed  CAS  Google Scholar 

  8. Hess DC: Cerebral lupus vasculopathy: mechanisms and clinical relevance. Ann N Y Acad Sci 1997, 823:154–168. The clinical manifestations of SLE-related vascular disease are discussed. The pathophysiology of vascular disease in SLE is reviewed.

    Article  PubMed  CAS  Google Scholar 

  9. Rodriguez AS, Oterino JAM, Hernandez PA: Lupus myelitis. Arch Intern Med 1998, 158(20):2267–2268.

    Article  PubMed  CAS  Google Scholar 

  10. Carbotte RM, Denburg SD, Denburg JA: Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986, 174:357–364.

    Article  PubMed  CAS  Google Scholar 

  11. Denburg SD, Carbotte RM, Denburg JA: Cognition and mood in systemic lupus erythematosus. Ann N Y Acad Sci 1997, 823:45–59.

    Article  Google Scholar 

  12. Petri M: Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(suppl 1):16–22.

    Article  Google Scholar 

  13. Dooley MA, Falk RJ: Immunosuppressive therapy of lupus nephritis. Lupus 1999, 7:630–634.

    Article  Google Scholar 

  14. Neuwelt CM, Lacks S, Kaye BR, et al.: Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995, 98:32–41.

    Article  PubMed  CAS  Google Scholar 

  15. Heyneman CA, Gudger CA, Beckwith JV: Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Ann Pharmacother 1997, 31:242–244.

    PubMed  CAS  Google Scholar 

  16. Rankin EC, Isenberg DA: IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus 1997, 6:390–394.

    PubMed  CAS  Google Scholar 

  17. Denburg SD, Carbotte RM, Ginsberg JS, et al.: The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997, 3:377–386.

    PubMed  CAS  Google Scholar 

  18. Menon S, Jameson-Shortall E, Newman SP, et al.: A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999, 42(4):735–741.

    Article  PubMed  CAS  Google Scholar 

  19. Hanly JG, Hong C, Smith S, et al.: A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999, 42(4):728–734.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Navarrete, M.G., Brey, R.L. Neuropsychiatric systemic lupus erythematosus. Curr Treat Options Neurol 2, 473–485 (2000). https://doi.org/10.1007/s11940-000-0045-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-000-0045-7

Keywords

Navigation